Diagnosis & Care

Cunningham Panel vs. Neural Zoomer for PANS/PANDAS

November 15, 20263 min readBy Liss Kron
A father holding his daughter's hand in a clinic after a blood test.

When a child changes, we need to investigate. Sudden changes in behavior, compulsions, tics, anxiety, food restriction or regression deserve a careful evaluation. In my Instagram post, I compared two blood-test panels families may hear about when discussing PANS/PANDAS: the Cunningham Panel and Neural Zoomer.

What does the Cunningham Panel measure?

The Cunningham Panel—now called the Autoimmune Brain Panel by its laboratory—contains five assays related to neuronal antibodies and CaMKII signaling activity. The slides group them this way:

  • Dopamine receptors D1 and D2: two antibody measurements.
  • Tubulin: an antibody measurement against a structural protein.
  • Lysoganglioside GM1: another neuronal antibody measurement.
  • CaMKII: a laboratory assay of cell-signaling activity stimulated by the patient’s serum.

Some clinicians use these results as complementary information when investigating possible immune involvement in neuropsychiatric symptoms. The panel does not confirm or rule out PANS/PANDAS by itself. Results need to be considered alongside symptoms, medical history and other findings.

What is Neural Zoomer?

The carousel calls it “NeuroZoomer Plus.” Vibrant’s product was named Neural Zoomer Plus and is now called Neural Zoomer. It is a commercial panel examining a broader range of antibodies related to the nervous system.

  • It looks at antibodies associated with neural proteins and possible neurological autoimmunity.
  • It may provide information for a clinician investigating an immune-related neurological concern.
  • The clinician must decide whether the tested antibodies are relevant to the child’s symptoms.

It is not a specific diagnostic test for PANS/PANDAS. A broader panel does not replace a focused clinical evaluation.

Medical use, insurance and IVIG

The post distinguishes the Cunningham Panel’s use in PANS/PANDAS discussions from Neural Zoomer’s use in some functional-medicine settings. That is separate from whether an insurer will pay for testing or authorize IVIG.

  • Test coverage: ask about the exact panel before collection. Moleculera’s insurance checklist says it is out of network and coverage cannot be guaranteed.
  • IVIG authorization: neither panel automatically secures approval. The treating specialist and insurer need to address the clinical case and the plan’s requirements.
  • Keep the questions separate: “Will this test help evaluate my child?” and “What will our insurance cover?” require separate answers.

What if the result is positive?

A positive result can identify an abnormal measured marker. It does not automatically show that the marker is causing the symptoms. The slides ask the specialist to consider:

  1. Which symptoms the child has and when they began.
  2. Whether the clinical picture suggests autoimmune disease.
  3. Whether other studies support or contradict that explanation.
  4. Whether other neurological, infectious or immune causes need investigation.

The goal is an explanation that fits the child—not simply a positive result.

What if the result is negative?

  • A negative result does not automatically exclude PANS/PANDAS.
  • No single accepted biomarker confirms or excludes these conditions on its own.
  • The evaluation still considers onset, symptom progression, medical history and appropriate investigations.

Our testing discussion guide can help you prepare for that conversation.

Our children deserve answers

A previous autism diagnosis should not prevent investigation of new symptoms or regression. Families deserve professionals who listen, evaluate and explain their decisions. We need better research, diagnostic tools and access to specialists.

We are looking for answers that help our children. With God beside us, we keep moving forward with faith, knowledge and perseverance.

Follow Liss KronFacebook group